Search

Your search keyword '"Aljama, Pedro"' showing total 409 results
Start Over Author "Aljama, Pedro"
409 results on '"Aljama, Pedro"'

1. 5G Technology for Next-Generation Wireless Consist Networks in Railways

Author

Larrañaga, Ana, Arriola, Aitor, Martinez, Imanol, Aljama, Pedro, Härri, Jérôme, Lopez, Igor, Fuhr, Uwe, Straub, Marvin, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Woeginger, Gerhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Moreno García-Loygorri, Juan, editor, Pérez Yuste, Antonio, editor, and Berbineau, Marion, editor

Published
2021
Full Text
View/download PDF

10. Eculizumab in secondary atypical haemolytic uraemic syndrome

Author

Cavero, Teresa, Rabasco, Cristina, López, Antía, Román, Elena, Ávila, Ana, Sevillano, Ángel, Huerta, Ana, Rojas-Rivera, Jorge, Fuentes, Carolina, Blasco, Miquel, Jarque, Ana, García, Alba, Mendizabal, Santiago, Gavela, Eva, Macía, Manuel, Quintana, Luis F., Romera, Ana María, Borrego, Josefa, Arjona, Emi, Espinosa, Mario, Portolés, José, Gracia-Iguacel, Carolina, González-Parra, Emilio, Aljama, Pedro, Morales, Enrique, Cao, Mercedes, de Córdoba, Santiago Rodríguez, and Praga, Manuel

Published
2017
Full Text
View/download PDF

16. Darbepoetin-[alpha] treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model

Author

Canadillas, Sagrario, Ortega, Rosa, Estepa, Jose-Carlos, Egea, Jeronimo, Gonzalez-Menehen, Alberto, Perez-Seoane, Carlos, Lopez-Andreu, Maria, Ramirez, Rafael, Tetta, Ciro, Rodriguez, Mariano, Martin-Malo, Alejandro, and Aljama, Pedro

Subjects
Erythropoietin -- Physiological aspects, Erythropoietin -- Genetic aspects, Erythropoietin -- Research, Glomerulonephritis -- Risk factors, Glomerulonephritis -- Genetic aspects, Glomerulonephritis -- Care and treatment, Glomerulonephritis -- Research, Immunohistochemistry -- Usage, Biological sciences
Abstract

Recent studies have demonstrated that erythropoietin (EPO) and its analogs induce cytoprotective effects on many nonerythroid ceils. In this study, we examined whether darbepoetin-[alpha] might prevent glomerular lesions in the Thy-1.1 model of glomerulonephritis (Thy-1-GN). GN was induced in Wistar rats by a single injection of monoclonal anti-Thy-l.1 antibody. Rats were killed at 24 h, 72 h, 7 days, 10 days, or 15 days after antibody injection. Kidneys were removed for histological analysis, and proteinuria was measured. Because at day 7 the maximal degree of renal damage and proteinuria was found, the effect of darbepoetin-[alpha] was tested at day 7 and two different protocols of administration were used; After anti-Thy-1.1 injection, rats received two doses of darbepoetin-[alpha] or vehicle at days 0 and 4 or at days 4 and 6. At day 7, proteinuria, plasma creatinine concentration, and renal morphology analysis were performed. Also, [alpha]-actin, desmin, caspase-3, and Ki67 protein expression were evaluated by immunohistochemistry. Our results showed that in both protocols of administration, darbepoetin-[alpha] treatment decreased proteinuria in Thy-1-GN rats and this effect correlated with the improvement in renal morphology. Glomerular lesions, [alpha]-actin, and caspase-3 protein expression, observed in most glomeruli of Thy-I-GN rats, were significantly reduced in darbepoetin-[alpha]-treated rats, while cell proliferation was significantly enhanced. The results indicate that darbepoetin-[alpha] treatment promotes glomerular recovery. erythropoietin analog; cytoprotective effects; glomerular regeneration doi: 10.1152/aj prenal.00343.2009

Published
2010

18. Coupling of endothelial injury and repair: an analysis using an in vivo experimental model

Author

Nogueras, Sonia, Merino, Ana, Ojeda, Raquel, Carracedo, Julia, Rodriguez, Mariano, Martin-Malo, Alejandro, Ramirez, Rafael, and Aljama, Pedro

Subjects
Vascular endothelium -- Research, Apoptosis -- Research, Erythropoietin -- Research, Cellular control mechanisms -- Research, Epithelial cells -- Research, Cardiovascular research, Biological sciences
Abstract

The repair of the endothelium after inflammatory injury is essential to maintaining homeostasis. The link between inflammation-induced endothelial damage and repair has not been fully characterized in vivo. We have developed a rat model to evaluate the coupling of lipopolysaccharide (LPS)-induced endothelial injury and repair. Aortic endothelium injury was analyzed by both inmunohistochemistry and flow cytometry to quantify the number of endothelial cells and the percentage of apoptotic endothelial cells. We have also identified the percentage of circulating angiogenic cells capable of repairing the damaged endothelium. Erythropoietin was administered to inhibit LPS-induced endothelial apoptosis. Loss of the normal endothelial structure was observed in the aorta of the animals treated with LPS. Eight hours after LPS administration, the number of endothelial cells decreased by 40%, returning to normal after 24 h. There was a three-fold increase in the percentage of circulating angiogenic cells, which did not return to normal levels until 48 h after LPS administration. Circulating angiogenic cell levels did not change when LPS-induced endothelial damage was prevented by erythropoietin. The endothelial injury caused by inflammation activates the mobilization of circulating angiogenic cells, thus completing endothelial repair. Inflammation without endothelial injury does not trigger the mobilization of circulating angiogenic cells. endothelium; lipopolysaccharide; apoptosis; circulating angiogenic cells; erythropoietin

Published
2008

26. Inflammation, Senescence and MicroRNAs in Chronic Kidney Disease

Author

Carmona, Andres, primary, Guerrero, Fatima, additional, Jimenez, Maria Jose, additional, Ariza, Francisco, additional, Agüera, Marisa L., additional, Obrero, Teresa, additional, Noci, Victoria, additional, Muñoz-Castañeda, Juan Rafael, additional, Rodríguez, Mariano, additional, Soriano, Sagrario, additional, Moreno, Juan Antonio, additional, Martin-Malo, Alejandro, additional, and Aljama, Pedro, additional

Published
2020
Full Text
View/download PDF

27. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients.

Author

de Mier, M. Victoria Pendon-Ruiz, primary, Ojeda, Raquel, additional, Álvarez-Lara, M. Antonia, additional, Navas, Ana, additional, Alonso, Corona, additional, Caballero-Villarraso, Javier, additional, Aljama, Pedro, additional, Álvarez, Miguel A., additional, Soriano, Sagrario, additional, Rodríguez, Mariano, additional, and Martín-Malo, Alejandro, additional

Published
2020
Full Text
View/download PDF

31. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis

Author

Pérez-García, Rafael, Varas, Javier, Cives, Alejandro, Martín-Malo, Alejandro, Aljama, Pedro, Ramos, Rosa, Pascual, Julio, Stuard, Stefano, Canaud, Bernard, Merello, José Ignacio, and ORD group

Subjects
Male, medicine.medical_specialty, 030232 urology & nephrology, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Renal Dialysis, hemic and lymphatic diseases, Internal medicine, medicine, Risk of mortality, Humans, Mortality, Renal Insufficiency, Chronic, Propensity Score, Survival rate, Survival analysis, Aged, Retrospective Studies, Transplantation, Proportional hazards model, business.industry, Retrospective cohort study, Prognosis, medicine.disease, Hospitalization, Survival Rate, Nephrology, Propensity score matching, Cohort, Hematinics, Female, business, Kidney disease
Abstract

Background Erythropoiesis-stimulating agents (ESAs) are widely used to treat anaemia in patients with chronic kidney disease. The issue of ESA safety has been raised in multiple studies, with correlates derived for elevated cancer incidence and mortality. Whether these associations are related to ESA dose or the typology of the patient remains obscure. Methods A multicentre, observational retrospective propensity score-matched study was designed to analyse the effects of weekly ESA dose in 1679 incident haemodialysis (HD) patients. ESA administration was according to standard medical practice. Patients were grouped as quintiles, according to ESA dose, in order to compare mortality and hospitalization data. Using propensity score matching (PSM), we defined two groups of 324 patients receiving weekly threshold ESA doses of either > or ≤8000 IU. Results Kaplan-Meier survival curves indicated significant increases in the risk of mortality in patients administered with high doses of ESAs (>8127.4 IU/week). Multivariate Cox models identified a high ESA dose as an independent predictor for all-cause and cardiovascular (CV) mortality. Moreover, logistic regression models identified high ESA doses as an independent predictor for all-cause, CV and infectious hospitalization. PSM analyses confirmed that weekly ESA doses of >8000 IU constitute an independent predictor of all-cause mortality and hospitalization, even though the adjusted cohort displayed the same demographic features, inflammatory profile, clinical HD parameters and haemoglobin levels. Conclusions Our data suggest that ESA doses of >8000 IU/week are associated with an increased risk of all-cause mortality and hospitalization in HD patients.

Published
2017

38. The Authors Reply

Author

Ramos, Rosa, de Francisco, Angel Luis M., Merello, Ignacio, Canaud, Bernard, Varas, Javier, Stuard, Stefano, Pascual Santos, Julio, Aljama, Pedro, Optimizing Results in Dialysis (ORD) group, Fresenius Medical Care, Marqués de Valdecilla University Hospital [Santander], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Fresenius Medical Care [Bad Homburg], IMIM-Hospital del Mar, Generalitat de Catalunya, Instituto Maimonides de Investigación Biomédica de Cordoba (IMIBIC), Universidad de Córdoba [Cordoba]-Hospital Universitario Reina Sofía, and Instituto de Salud Carlos III [Madrid] (ISC)

Subjects
Coronary Thrombosis, Myocardial Ischemia, Hemodiàlisi -- Mortalitat, 030204 cardiovascular system & hematology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Nephrology, Hemodialysis, Proton Pump Inhibitors (PPIs), Homeostasis, 030212 general & internal medicine, Letters to the Editor
Abstract

International audience; The scope of the use of proton pump inhibitors (PPIs) in hemodialysis patients is really worrying because of its widespread use, often in the absence of medical supervision and its implications have potential adverse effects.

Published
2019

44. Introduction

Author

Aljama, Pedro, Martin-Malo, Alexandro, and Tetta, Ciro

Published
2006

50. Pancreatic autoantibodies and CD14+CD16+ monocytes subset are associated with the impairment of ß-cell function after simultaneous pancreas-kidney transplantation

Author

Rodelo-Haad, Cristian, Agüera, María Luisa, Carmona, Andrés, Navarro, María Dolores, Carracedo Añón, Julia María, Rodríguez-Benot, Alberto, Aljama, Pedro, Rodelo-Haad, Cristian, Agüera, María Luisa, Carmona, Andrés, Navarro, María Dolores, Carracedo Añón, Julia María, Rodríguez-Benot, Alberto, and Aljama, Pedro

Abstract

Pancreatic autoantibodies (AAb) has been associated with a worse pancreas graft survival after simultaneous pancreas-kidney transplantation (SPK). However, due to the variable time for AAb to become positive and the lack of early biomarkers suggesting such autoimmune activation, the mechanisms leading ß-cell destruction remain uncertain. The present study aimed to evaluate the association between post-transplant AAb and the functional impairment of the pancreatic ß-cell and also the association of such AAb with inflammation after SPK. In a longitudinal study, we analyzed the impact of post-transplant glutamic acid decarboxylase (GAD-65) and the insulinoma-associated autoantigen 2 (IA-2) AAb on pancreas graft function. Serum Hb1Ac and C-peptide (C-pep) were longitudinally compared between a group with positive posttransplant AAb (AAb+; n = 40) and another matched group with negative AAb (AAb-; n = 40) until the fifth year following seroconversion. In the cross-sectional analysis, we further evaluated the systemic signatures of inflammation by measuring pro-inflammatory CD14+CD16+ monocytes by flow-cytometry and interleukin 17-A serum levels in 38 SPK recipients and ten healthy controls. In the longitudinal study, patients with AAb+ showed higher levels of Hb1Ac (p<0.001) and lower C-pep levels (p<0.001) compared to those who remained AAb- throughout the follow-up. In the cross-sectional study, AAb+ patients showed a higher percentage of CD14+CD16+ monocytes compared with those with AAb- and the healthy controls (6.70±4.19% versus 4.0±1.84% and 3.44±0.93%; p = 0.026 and 0.009 respectively). Also, CD14+CD16+ monocytes correlated with Hb1Ac and C-pep serum levels. Multivariate logistic regression showed that posttransplant AAb+ was independently associated with a higher percentage of pro-inflammatory monocytes (adjusted-OR 1.59, 95%CI 1.05–2.40, p = 0.027). The group of patients with positive AAb also showed higher levels of IL17A as compared with the other groups (eith, En los pacientes con enfermedad renal terminal (ERT) secundaria a Diabetes tipo 1 (T1D), el trasplante simultáneo de páncreas y riñón (SPK) se ha convertido en la mejor opción para restaurar el control de la glucosa y la función renal. Después del SPK, y a pesar de la terapia inmunosupresora, la aparición de autoanticuerpos pancreáticos (AAb) se han asociado con una peor supervivencia del injerto de páncreas. Sin embargo, todavía no se conocen los mecanismos implicados en este proceso. El objetivo del presente estudio fue evaluar la asociación entre AAb postrasplante y el deterioro funcional de la célula ß pancreática, así como la asociación de los AAb con la inflamación después del SPK. En un estudio que incluyó 38 receptores SPK y diez controles sanos, analizamos señales de inflamación caracterizando los monocitos pro-inflamatorios CD14+CD16+ por citometría de flujo y los niveles séricos de interleucina 17-A. Un análisis de regresión logística multivariada mostró que el nivel de AAb+ postrasplante se asoció de forma independiente con un mayor porcentaje de monocitos proinflamatorios y con niveles más altos de IL17A. Con los resultados obtenidos, se plantea la hipótesis de que uno de los posibles mecanismos a través de los cuales se promueve el incremento de AAb+ postrasplante SPK es la inducción de la microinflamación., Instituto de Salud Carlos III (ISCIII) / FEDER, Depto. de Genética, Fisiología y Microbiología, Fac. de Ciencias Biológicas, TRUE, pub

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results